KEDPLASMA Advances Long-Range Growth Plan

Fort Lee, NJ—KEDPLASMA, one of the world’s leading collectors of high-quality human blood plasma, has advanced its long-range growth plans by expanding a plasma supply agreement with ImmunoTek Bio Centers, LLC. The agreement ensures that considerable volumes of plasma will be available to Kedrion Biopharma, parent company of KEDPLASMA, for the manufacture of therapies used in treating rare and serious disorders.

IMMUNOTEK will develop for KEDPLASMA a total of 28 plasma collection centers in the U.S. The agreement was made in parallel with KEDPLASMA acquiring two plasma collection centers from IMMUNOTEK, one in Shreveport, LA and another in Ocala, FL, Both centers are licensed by the U.S. Food and Drug Administration and by European regulatory authorities.

KEDPLASMA collects plasma for its parent company, Kedrion Biopharma, which, in turn, uses it in the production of safe, effective, plasma-derived therapies that treat a range of rare and serious health conditions, including hemophilia, immunological and neurological conditions, and certain acute, life-threatening conditions requiring treatment in the critical care setting.

KEDPLASMA is also one of the world’s leading suppliers of high-titer rabies plasma.
KEDPLASMA’s amended agreement with ImmunoTek Bio Centers, LLC and the acquisition of the two plasma collection centers is another step forward in a five-year strategic plan to increase the plasma supply and number of centers the Company operates in the United States so that more patients may have access to the therapies offered by Kedrion Biopharma.

“The expansion of the agreement further strengthens the ability of Kedrion Biopharma to manufacture and distribute the therapies so needed by patients who have certain rare and serious health conditions,” said Helen Nasser, KEDPLASMA United States Managing Director. “It is always exciting to bring on new centers and to be able to welcome new staff in a fully functioning, licensed center. This allows the Company to instantly focus on increasing production and insuring we can meet the growth plan and plasma needs of our parent.”

”KEDPLASMA has acquired a total of four plasma collection centers from IMMUNOTEK since 2015. “We are excited to enhance our relationship with Kedrion Biopharma, a fast-growing leader in the plasma therapeutics business,” said Jerome Parnell III, IMMUNOTEK’s CEO and President, “Our commitment to developing a safe and predictable supply of plasma will continue to be the foundation of our business values and the core sustainability of IMMUNOTEK’s future as one of the world’s largest independent plasma suppliers.”


About ImmunoTek Bio Centers LLC

ImmunoTek BioCenters is an emerging bio-tech company committed to the safe collection and procurement of human blood plasma from the public. The management team has extensive experience in the blood, plasma, and biopharma industries. Through contracts and strategic agreements with pharmaceutical companies, IMMUNOTEK is fully capable of constructing, opening, FDA/EU licensing, and managing multiple plasma collection sites and plasma supply contracts in order to meet on going demand in the plasma proteins therapeutics market. Growth of current therapeutic drugs and vaccines as well as additional new therapeutic indications expected to put considerable strain on global blood plasma supply. IMMUNOTEK currently owns and operates plasma collection centers in the USA and has over 40 collection centers in development through 2020.